In a report released yesterday, Steven Halper from Cantor Fitzgerald reiterated a Buy rating on Tivity Health Inc (TVTY), with a price target of $40. The company’s shares closed yesterday at $21.65, close to its 52-week low of $20.64.
Halper observed:
“. We reiterate our Overweight rating on TVTY shares, but lower our 12-month price target to $40 from $52. After the close on Tuesday, February 19, TVTY reported 4Q18 results, with revenue essentially in line with our estimate and FactSet consensus, while adjusted EPS were well-above. TVTY also issued preliminary 2019 guidance, which reflects a greater-than-expected impact from the loss of UnitedHealth Group lives (UNH, OW). Although it is probably safe to assume that UNH will move the remaining states in 2020 (individual MA), TVTY maintains that investments to drive enrollment and utilization are contributing positively.”
According to TipRanks.com, Halper is a top 100 analyst with an average return of 20.6% and a 67.8% success rate. Halper covers the Services sector, focusing on stocks such as WellCare Health Plans, Evolent Health, and Centene Corp.
Tivity Health Inc has an analyst consensus of Strong Buy, with a price target consensus of $36.20, which is a 67.2% upside from current levels. In a report released today, Oppenheimer also reiterated a Buy rating on the stock with a $31 price target.
See today’s analyst top recommended stocks >>
Tivity Health Inc’s market cap is currently $867M and has a P/E ratio of 12.07. The company has a Price to Book ratio of 2.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tivity Health, Inc. engages in the development and provision of network solutions and health management services. It offers rehabilitative therapy, chiropractic procedure, alternative medicines, and health and fitness programs under the SilverSneakers, Prime Fitness, and WholeHealth Living trademarks.
